AIMS: To examine the HBV and HCV markers of injecting drug users on methadone maintenance, and the feasibility of vaccination at the drug clinic. METHODS: Systematic serological testing of patients for hepatitis B and C was undertaken, and free hepatitis B vaccination was offered via arranged clinic appointments. RESULTS: Hepatitis B serology was obtained in 163 of the 220 clinic patients. 85 (52.1%) patients had evidence of hepatitis B exposure, and 3 (1.8%), of previous vaccination. Positive hepatitis B markers were associated with increasing age (p=0.004), and the duration of injecting prior to treatment (p=0.008). Hepatitis B and C serology was obtained for 153 patients, with 76 (49.7%) having evidence of dual exposure. 164 (84.1%) of 195 patients were positive for antibody to hepatitis C. Completion of the vaccine course was lower than anticipated (36.5% of HBV negative patients). CONCLUSIONS: The high rates of hepatitis B exposure in injecting drug users on methadone treatment confirm the need for hepatitis B vaccination, particularly in view of their endemic hepatitis C infection. Monitoring of this group for the development of chronic liver disease and hepatocellular carcinoma is recommended. Routine cost-free vaccination of patients on entering drug treatment, using a rapid vaccination schedule, may improve compliance.
AIMS: To examine the HBV and HCV markers of injecting drug users on methadone maintenance, and the feasibility of vaccination at the drug clinic. METHODS: Systematic serological testing of patients for hepatitis B and C was undertaken, and free hepatitis B vaccination was offered via arranged clinic appointments. RESULTS:Hepatitis B serology was obtained in 163 of the 220 clinic patients. 85 (52.1%) patients had evidence of hepatitis B exposure, and 3 (1.8%), of previous vaccination. Positive hepatitis B markers were associated with increasing age (p=0.004), and the duration of injecting prior to treatment (p=0.008). Hepatitis B and C serology was obtained for 153 patients, with 76 (49.7%) having evidence of dual exposure. 164 (84.1%) of 195 patients were positive for antibody to hepatitis C. Completion of the vaccine course was lower than anticipated (36.5% of HBV negative patients). CONCLUSIONS: The high rates of hepatitis B exposure in injecting drug users on methadone treatment confirm the need for hepatitis B vaccination, particularly in view of their endemic hepatitis C infection. Monitoring of this group for the development of chronic liver disease and hepatocellular carcinoma is recommended. Routine cost-free vaccination of patients on entering drug treatment, using a rapid vaccination schedule, may improve compliance.
Authors: Alan D Tice; Michael Bannan; Kay Bauman; Tarquin Collis; Alba Hall; William Haning; Shoshana Hannemann; C Bradley Hare; Joseph Humphry; Robert Jao; Carroll Leevy; Heather Lusk; Edward Ochoa; Neal Palafox; Nancy Withers; Kenneth Akinaka Journal: Hawaii Med J Date: 2010-04
Authors: Imke Schreuder; Marianne Ab van der Sande; Matty de Wit; Monique Bongaerts; Charles Ab Boucher; Esther A Croes; Maaike G van Veen Journal: Harm Reduct J Date: 2010-10-26
Authors: Yiqing Hu; Lauretta E Grau; Greg Scott; Karen H Seal; Patricia A Marshall; Merrill Singer; Robert Heimer Journal: Am J Prev Med Date: 2008-07 Impact factor: 5.043
Authors: Fabio Lugoboni; Gianluca Quaglio; Paolo Civitelli; Paolo Mezzelani Journal: Int J Environ Res Public Health Date: 2009-01-22 Impact factor: 3.390